Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases

Melanoma Research

Volumn 15, Issue 5, 2005, Pages 427-434

  Kirschner, Martin ^a   Helmke, Burkhard ^a   Starz, Hans ^b   Benner, Axel ^c   Thome, Marianne ^a   Deichmann, Martin ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b KLINIKUM AUGSBURG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

B raf; Lymph node metastases; Melanoma; Oncogene; Polymerase chain reaction; Single strand conformational polymorphism

Indexed keywords

B RAF KINASE; PROTEIN SERINE THREONINE KINASE; RAS PROTEIN;

AMINO ACID ANALYSIS; AMPLICON; ARTICLE; CANCER SURGERY; CELL TRANSFORMATION; CONTROLLED STUDY; GEL ELECTROPHORESIS; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MELANOMA; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; SINGLE STRAND CONFORMATION POLYMORPHISM; SOMATIC MUTATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; V599E GENE; V599K GENE;

EXONS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; MUTATION; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 27644599364     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200510000-00011     Document Type: Article

References (47)

1. Brochez L, Naeyaert JM. Understanding the trends in melanoma incidence and mortality, where do we stand? Eur J Dermatol 2000; 10:71-75.
2. Deichmann M, Thome M, Benner A, Egner U, Hartschuh W, Näher H. PTEN/MMAC1 expression in melanoma resection specimens. Br J Cancer 2002; 87:1431-1436.
3. Davies H, Bignell GR, Cox C, Stephens R Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.
4. Satyamoorthy K, Li G, Gerreo MR, Brose MS, Volpe P, Weber BL, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003; 63:756-759.
5. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33:19-20.
6. Deichmann M, Thome M, Benner A, Näher H. B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome. Oncology 2004; 66:411-419.
7. Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003; 63:3955-3957.
8. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62:6997-7000.
9. Wagner SN, Ockenfels HM, Wagner C, Hofler H, Goos M. Ras gene mutations, a rare event in nonmetastatic primary malignant melanoma. J Invest Dermatol 1995; 104:868-871.
10. Hothorn T. On exact rank tests in R. R Wews 2001; 1:11-12.
11. R Development Core Team. R, a language and environment for statistical computing.Vienna: R Foundation for Statistical Computing; 2003.
12. Daya-Grosjean L, Dumaz N, Sarasin A. The specificity of p53 mutation spectra in sunlight induced human cancers. J Photochem Photobiol 1995; 28:115-124.
13. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene, clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-4878.
14. Moles UP, Moyret C, Guillot B, Jeanteur P, Guilhou JJ, Theillet C, et al. p53 gene mutations in human epithelial skin cancers. Oncogene 1993; 8:583-588.
15. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, et al. Mutation hotspots due to sunlight in the p53 gene of nonmetanoma skin cancers. Proc Natl Acad Sci USA 1993; 90:4216-4220.
16. Peyssonnaux C, Eychène A. The Raf/MEK/ERK pathway, new concepts of activation. Biol Cell 2001; 93:53-62.
17. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, et al. Essential role for oncogenic Ras in tumor maintenance. Nature 1999; 400:468-472.
18. Jiveskog S, Ragnarsson-Olding B, Platz A, Ringborg U. N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol 1998; 111:757-761.
19. van Elsas A, Zerp SF, van der Flier S, Kruse KM, Aarnoudse C, Hayward NK, et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996; 149:739-744.
20. Kraehn GM, Schartl M, Peter RU. Human malignant melanoma, a genetic disease. Cancer 1995; 75:1228-1237.
21. van't Veer LJ, Burgering BMT, Versteeg R, Boot AJM, Ruiter DJ, Osanto S, et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989; 9:3114-3116.
22. Barnier JV, Papin C, Eychène A, Lecoq O, Calothy G. The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. J Biol Chem 1995; 270:23381-23389.
23. Eychène A, Barnier JV, Dezelee P, Marx M, Laugier D, Calogeraki I, et al. Quail neuroretina c-Rmil (B-raf) proto-oncogene cDNAs encode two proteins of 93.5 and 95 kDa resulting from alternative splicing. Oncogene 1992; 7:1315-1323.
24. Marx M, Eychène A, Laugier D, Bechade C, Crisanti P, Dezelee P, et al. A novel oncogene related to c-mil is transduced in chicken neuroretina cells induced to proliferate by infection with an avian lymphomatosis virus. EMBO J 1988; 11:3369-3373.
25. V599E as a melanoma susceptibility mutation. Int J Cancer 2003; 106:78-80.
26. Cohen Y, Goldenberg-Cohen N, Parrella P, Chowers I, Merbs SL, Peer J, et al. Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44:2876-2878.
27. Edmunds SC, Cree IA, Nicolantonio FD, Hungerford JL, Hurren JS, Kelsell DP. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer 2003; 88:1403-1405.
28. Cruz F III, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 2003; 63:5761-5766.
29. Rimoldi D, Salvi S, Liènard D, Lejeune FJ, Speiser D, Zografos L, et al. Lack of BRAF mutations in uveal melanoma. Cancer Res 2003; 63:5712-5715.
30. Laud K, Kannengiesser C, Avril MF, Chompret A, Stoppa-Lyonnet D, Desjardins L, et al. BRAF as a melanoma susceptibility candidate gene? Cancer Res 2003; 63:3061-3065.
31. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003; 9:6483-6488.
32. Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33:19-20.
33. Mercer KE, Pritchard CA. Raf proteins and cancer, B-Raf is identified as a mutational target. Biochim Biophys Acta 2003; 1653:25-40.
34. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003; 63:3883-3885.
35. Halaban R. The regulation of normal melanocyte proliferation. Pigment Cell Res 2000; 13:4-14.
36. Busca R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychène A, et al. Ras mediates the cDMAP-dependent activation of extracellular signal-related kinases (ERKs) in melanocytes. EMBO J 2000; 19:2900-2910.
37. Englaro W, Rezzonico R, Durand-Clement M, Lallemand D, Ortonne JP, Ballotti R. Mitogen-activated protein kinase pathway and AP-1 are activated during cAMP-induced melanogenesis in B-16 melanoma cells. J Biol Chem 1995; 270:24315-24320.
38. Imokawa G, Yada Y, Miyagishi M. Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J Biol Chem 1992; 267:24675-24680.
39. Yada Y, Higuchi K, Imokawa G. Effects of endothelins on signal transduction and proliferation in human melanocytes. J Biol Chem 1991; 266:18352-18357.
40. Imokawa G, Yada Y, Kimura M. Signalling mechanisms of endothelin-induced mitogenesis and melanogenesis in human melanocytes. Biochem J 1996; 314:305-312.
41. Swope VB, Medrano EE, Smalara D, Abdel-Malek ZA. Long-term proliferation of human melanocytes is supported by the physiologic mitogens alpha-melanotropin, endothelin-1, and basic fibroblast growth factor. Exp Cell Res 1995; 217:453-459.
42. Imokawa G, Kobayasi T, Miyagishi M. Intracellular signaling mechanisms leading to synergistic effects of endothelin-1 and stem cell factor on proliferation of cultured human melanocytes, cross-talk via trans-activation of the tyrosine kinase c-kit receptor. J Biol Chem 2000; 275:33321-33328.
43. Cohen Y, Xing M, Mambo E, Quo Z, Wu Z, Trink B, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95:625-627.
44. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003; 22:4578-4580.
45. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer, genetic evidence for constitutive activation of the RET/PCR-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63:1454-1457.
46. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998; 273:18623-18632.
47. Kelemen BR, Hsiao K, Goueli SA. Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides. J Biol Chem 2002; 277:8741-8748.